Hikal, the emerging pharma and chemicals company, witnessed a catastrophic second quarter, marred by operational challenges. A planned shutdown for its Bengaluru plant was factored in while shutdowns in Mahad and Taloja plants proved to be Black Swan events.
Moneycontrol's Sakshi Batra does a 3-Point Analysis to understand the company's earnings fine print and the outlook on the company.
Watch the video for more.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
